GlassScriptPhysician profile
Sean P Boyle
NPI 1629060603
$3,767.63
in general payments reported to CMS, 2019-2025
24 companies · $613 in 2025
The $613 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $1,156 · 2021: $39.70 · 2022: $99.94 · 2023: $415 · 2024: $643 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,640 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,639.66 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,104.14 | 2020-2022 | |
| Acell, INC. | $782.79 | 2019 | |
| Lilly USA, LLC | $420.88 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $375.21 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $311.36 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $173.72 | 2025 | |
| Welch Allyn | $100.00 | 2020 | |
| Pfizer INC. | $95.78 | 2024-2025 | |
| Abbvie INC. | $69.39 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $35.51 | 2023-2024 | Verquvo, Vaxneuvance, Gardasil |
| Astrazeneca Pharmaceuticals LP | $31.64 | 2019-2025 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.01 | 2024 | Xifaxan, Trulance |
| Inspire Medical Systems, INC. | $27.05 | 2024 | Inspire |
| Exact Sciences Corporation | $24.09 | 2025 | Cologuard Collection Kit |
| Abbott Laboratories | $21.74 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $21.14 | 2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.01 | 2023 | Tradjenta, Synjardy |
| Ibsa Pharma INC. | $18.71 | 2024 | Licart, Tirosint |
| Astellas Pharma US INC | $18.18 | 2023 | Veozah |
| Janssen Pharmaceuticals, INC | $18.00 | 2025 | Spravato |
| Kowa Pharmaceuticals America, INC. | $17.98 | 2025 | Zoryve |
| Biogen, INC. | $17.96 | 2021 | |
| Tolmar, INC. | $17.35 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $15.99 | 2023 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Boyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.